SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors.
Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed’s board after serving on it since July 1994. Ms. Gill’s appointment and Dr. Pace’s retirement both took effect Thursday, November 15.
Ms. Gill has more than 25 years’ experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Philips ASEAN & Pacific, overseeing Healthcare/Lighting and Consumer Lifestyle Products; senior vice president of International Sales; vice president of Asia for Philips Consumer Lifestyle Products; and various other senior roles in Philips Consumer Electronics businesses in the Netherlands, Hong Kong, Dubai and Singapore. From 2015 to 2016, she served as chief operations and marketing officer for HTC, Taiwan. Since 2016, she has been advisor to Delmedica Investments, a Singapore-based company focused on respiratory health and inventors of the X-Halo breath thermometer.
Ms. Gill is also a board director for Apollo Education and Training, a private company providing English teaching in Vietnam, and has held various leadership roles at the Singapore chapter of YPO, which provides growth and networking opportunities to CEOs worldwide.
"I’m very excited to welcome Harjit Gill to ResMed's Board," said ResMed Founder and Board Chairman Peter Farrell. "ResMed will greatly benefit from her vast experience, not only in healthcare and consumer technology, but across the many global regions where ResMed continues to expand its reach.
"I'd also like to thank Dr. Gary Pace for his valuable and effective guidance to ResMed during his 24 years of service as a director,” said Farrell, “including during the period of ResMed’s important transformation from medical device company to global leader in connected medical devices and out-of-hospital software.”
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 6 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
